OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading gene therapy specialist based in China, has entered into a partnership with fellow Chinese firm ImmVira. The collaboration pertains to the Biologics License Application (BLA) filing and the commercial industrialization of an oncolytic virus project. ImmVira, which is responsible for the filing, will also handle the commercial production services for the oncolytic virus products. The financial details of the agreement have not been disclosed.
ImmVira’s Clinical Trial Strengths and OBiO’s Comprehensive Capabilities
ImmVira, known for securing 4 clinical trial approvals in China and 3 in the United States, brings a robust portfolio of clinical development experience to the partnership. OBiO Technology, with its advanced process development capabilities and production expertise across multiple clinical GCT products, will offer ImmVira a comprehensive suite of Contract Development and Manufacturing Organization (CDMO) services. These services will span various stages, including process development, large-scale sample production, and clinical trial application support in both China and the United States.
The Synergy of the Partnership
This strategic alliance combines ImmVira’s clinical trial approvals and regulatory expertise with OBiO’s end-to-end CDMO services, positioning the partnership to efficiently navigate the complex landscape of oncolytic virus therapy development and commercialization. The collaboration aims to accelerate the path from laboratory research to commercial availability, potentially offering new treatment options for patients in need.-Fineline Info & Tech
